Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJETI.L Regulatory News (JETI)

  • There is currently no data for JETI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Company Update

20 Oct 2021 07:00

RNS Number : 5837P
JPMorgan European Invest Tst PLC
20 October 2021
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO, THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION FOR WHICH THE SAME COULD BE UNLAWFUL.

 

The information communicated in this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this information is considered to be in the public domain.

 

 

JPMorgan European Investment Trust Plc

Company Update

Legal Entity Identifier: 549300D8SPJFHBDGXS57

 

20th October 2021

 

The Board of JPMorgan European Investment Trust Plc (the "Company") stated in its annual report for the financial year ended 31 March 2021 that it was continuing to work with its investment manager, JPMorgan Asset Management (UK) Limited (the "Investment Manager"), to determine whether the Company provides a model which will provide a sustainable attractive return for the longer term.

The Board has now concluded a review of the Company and its strategy, which included considering various options to improve marketability and to broaden the appeal of the Company as well as to improve liquidity and to narrow the discount at which the Company's shares trade. The Board believes there remains a strong case for investment in Europe, with the broad universe of European equities providing quality diversification for UK investors. However, the Board is of the view that the Company's existing dual share class structure is unnecessarily complex and potentially presents a hurdle to those looking to invest. The Board believes that a single share class with a clearly defined investment process would enable a cogent investment approach and increase the Company's appeal.

The Board has therefore determined that it would be in the best interests of shareholders to consolidate the Company's Income Shares and Growth Shares into a single class of ordinary shares (the "New Ordinary Shares") (the "Consolidation"). The investment objective and investment policy of the New Ordinary Shares will be the same as that of the Company's Growth Shares, reflecting the Board's confidence in the Investment Manager's strength and depth of team, as well as its track record, which has performed strongly against the Company's benchmark and peers over the last 2 years being a particularly challenging period for active managers. Looking longer term, the Company has also outperformed its benchmark over 5 and 10 years.

The Consolidation will create a company with net assets of approximately £500m and should ensure the critical mass needed to attract investors - it is also expected that the increased size will have a beneficial impact on liquidity, which is expected to have an additional positive impact on the discount of the New Ordinary Shares. Conditional on the Consolidation, which requires the approval of the Company's shareholders, the Board also intends to introduce the following features which it believes will further appeal to investors:

1. Introduction of an enhanced income strategy to target a dividend of 4% p.a. (based on the net asset value of the New Ordinary Shares as at the end of the preceding financial year) - such strategy is differentiated to other European investment companies and makes use of the closed-ended structure;

2. Adoption of an active discount management policy with a commitment to keep any discount on the New Ordinary Shares to single digit levels, in normal market conditions;

3. Introduction of a performance-related tender offer - if NAV total return performance is behind the Company's benchmark (the MSCI Europe ex UK Index (total return) in sterling terms) over a five year period from Consolidation, a tender offer will be made for up to 25% of the outstanding share capital at NAV less costs;

4. Lower management fees - a reduced fee calculated on net assets of 0.55% p.a. up to £400m, 0.4% p.a. thereafter;

5. Reduction of the notice period to 6 months (from 12 months at present); and

6. Change of the Company's name to JPMorgan European Growth & Income plc, with the New Ordinary shares trading under a new ticker, JEGI.

The Company has consulted with shareholders representing material interests in both the Income Shares and the Growth Shares and they have indicated their support for these proposals. The Company expects to publish a circular and notice of meeting(s) in connection with the Consolidation in due course and aims, subject to approval of the Company's shareholders, to conclude the Consolidation and to introduce the above features by late 2021/early 2022.

 

For further information please contact:

 

JPMorgan Funds Limited

Tim Mitchell - 0207 742 8879

Winterflood Securities LimitedNeil Morgan - 020 3100 0292

 

The person responsible for arranging for the release of this announcement on behalf of the Company is Paul Winship of JPMorgan Funds Limited.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBLBDGCDBDGBC
Date   Source Headline
3rd Feb 20226:00 pmRNSJPMorgan European Investment Trust
3rd Feb 20222:57 pmRNSResults of Restructuring and Amendments to Listing
1st Feb 202211:25 amRNSNet Asset Value(s)
1st Feb 20229:19 amRNSTotal Voting Rights
31st Jan 202212:13 pmRNSGearing Announcement
31st Jan 202211:54 amRNSNet Asset Value(s)
28th Jan 202211:49 amRNSNet Asset Value(s)
27th Jan 202211:20 amRNSNet Asset Value(s)
26th Jan 202212:01 pmRNSNet Asset Value(s)
25th Jan 202211:58 amRNSNet Asset Value(s)
24th Jan 20221:52 pmRNSGearing Announcement
24th Jan 20221:01 pmRNSNet Asset Value(s)
24th Jan 202212:35 pmRNSResults of Meetings and Transaction Update
21st Jan 202212:28 pmRNSNet Asset Value(s)
20th Jan 202212:12 pmRNSNet Asset Value(s)
19th Jan 202211:45 amRNSNet Asset Value(s)
18th Jan 202211:06 amRNSNet Asset Value(s)
17th Jan 20224:59 pmRNSTransaction in Own Shares
17th Jan 202212:42 pmRNSTen Largest Investments
17th Jan 202211:51 amRNSGearing Announcement
17th Jan 202211:45 amRNSNet Asset Value(s)
14th Jan 202211:17 amRNSNet Asset Value(s)
13th Jan 202210:52 amRNSNet Asset Value(s)
12th Jan 20225:27 pmRNSTransaction in Own Shares
12th Jan 202210:39 amRNSNet Asset Value(s)
11th Jan 202210:58 amRNSNet Asset Value(s)
10th Jan 202211:46 amRNSGearing Announcement
10th Jan 202211:07 amRNSNet Asset Value(s)
7th Jan 202211:02 amRNSNet Asset Value(s)
6th Jan 202211:12 amRNSNet Asset Value(s)
5th Jan 202211:14 amRNSNet Asset Value(s)
4th Jan 20222:56 pmRNSTotal Voting Rights
4th Jan 20221:21 pmRNSGearing Announcement
4th Jan 20221:18 pmRNSNet Asset Value(s)
31st Dec 202111:46 amRNSNet Asset Value(s)
30th Dec 202111:04 amRNSNet Asset Value(s)
29th Dec 20215:21 pmRNSTransaction in Own Shares
29th Dec 202112:14 pmRNSGearing Announcement
29th Dec 202111:16 amRNSNet Asset Value(s)
24th Dec 202111:31 amRNSNet Asset Value(s)
23rd Dec 202110:44 amRNSNet Asset Value(s)
22nd Dec 202110:43 amRNSNet Asset Value(s)
22nd Dec 202110:13 amRNSDirectorate Change
21st Dec 202111:20 amRNSNet Asset Value(s)
20th Dec 20214:34 pmRNSPublication of Circular
20th Dec 202111:18 amRNSNet Asset Value(s)
20th Dec 202110:54 amRNSGearing Announcement
17th Dec 202111:27 amRNSNet Asset Value(s)
16th Dec 202111:09 amRNSNet Asset Value(s)
15th Dec 20214:25 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.